[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]

Autor: Loriot, Marie-Anne, Masskouri, Fadil, Carni, Paolo, Le Malicot, Karine, Seitz, Jean-François, Michel, Pierre, Legoux, Jean-Louis, Bouche, Olivier, André, Thierry, Faroux, Roger, Delaloge, Suzette, Malka, David, Guigay, Joël, Thariat, Juliette, Thomas, Fabienne, Barin-Le-Guellec, Chantal, Ciccolini, Joseph, Boyer, Jean-Christophe, Etienne-Grimaldi, Marie-Christine
Přispěvatelé: Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fédération Francophone de la Cancérologie Digestive, FFCD, Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), F2ME, PSA Peugeot - Citroën (PSA), PSA Peugeot Citroën (PSA)-PSA Peugeot Citroën (PSA)-Laboratoire Pluridisciplinaire de Recherche en Ingénierie des Systèmes, Mécanique et Energétique (PRISME), Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO), Regional Hospital of Orleans, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHD Vendée - Hôpital Les Oudairies [La Roche sur Yon], Institut Gustave Roussy (IGR), Onco-génétique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Medical Oncology Department [Nice], COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA)-UNICANCER-Université Côte d'Azur (UCA), Institute of Developmental Biology and Cancer (IBDC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Laboratoire de biochimie et biologie moléculaire, Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges)-Université d'Orléans (UO)-Ecole Nationale Supérieure d'Ingénieurs de Bourges (ENSI Bourges), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), UNICANCER-Université Côte d'Azur (UCA)-UNICANCER-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: francouzština
Rok vydání: 2019
Předmět:
Biomedical Research
Dihydropyrimidine Dehydrogenase Deficiency
MESH: Pharmacovigilance
[SDV]Life Sciences [q-bio]
Surveys
MESH: Health Care Surveys
Digestive System Neoplasms
MESH: Genotype
Pharmacovigilance
MESH: Practice Guidelines as Topic
Antineoplastic Combined Chemotherapy Protocols
MESH: Otorhinolaryngologic Neoplasms
Oncologists
MESH: Antimetabolites
Antineoplastic
Enquête
DPD
MESH: Antineoplastic Combined Chemotherapy Protocols
Practice Guidelines as Topic
Screening
Female
Fluorouracil
France
Dihydropyrimidine dehydrogenase
Fluoropyrimidine
Antimetabolites
Antineoplastic
Genotype
Breast Neoplasms
[SDV.BC]Life Sciences [q-bio]/Cellular Biology
Dihydropyrimidine déshydrogénase
Reimbursement Mechanisms
Toxicité
MESH: Reimbursement Mechanisms
MESH: Biology
Humans
Biology
Capecitabine
MESH: Humans
Toxicity
MESH: Digestive System Neoplasms
MESH: Biomedical Research
MESH: Oncologists
MESH: Capecitabine
MESH: France
Otorhinolaryngologic Neoplasms
Pyrimidines
Dépistage
Health Care Surveys
MESH: Pyrimidines
MESH: Dihydropyrimidine Dehydrogenase Deficiency
MESH: Female
MESH: Fluorouracil
MESH: Breast Neoplasms
Zdroj: Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2019, 106 (9), pp.759-775. ⟨10.1016/j.bulcan.2019.04.013⟩
Bulletin du Cancer, 2019, 106 (9), pp.759-775. ⟨10.1016/j.bulcan.2019.04.013⟩
ISSN: 0007-4551
1769-6917
DOI: 10.1016/j.bulcan.2019.04.013⟩
Popis: International audience; Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of early severe toxicities induced by fluoropyrimidines (FP). The French Group of Clinical Oncopharmacology (GPCO)-Unicancer and the French Pharmacogenetics Network (RNPGx) initiated two surveys, one addressed to oncologists, the other to biologists, in order to evaluate routine practices regarding DPD deficiency screening at national level, as well as compliance, motivations and obstacles for implementation of these tests. These anonymized online surveys were performed with the logistic assistance of the Francophone Federation of Digestive Oncology (FFCD) and the support of numerous medical and biological societies. The surveys were conducted in 2016-2017 before the creation of the French INCa/HAS expert panel, which contributed to the drafting of rules and recommendations for DPD deficiency screening published in December 2018. In all, 554 questionnaires from clinicians were analyzed (23% participation) and 35 from biologists. The main arguments raised by clinicians for justifying the limited practice of DPD deficiency screening were: the lack of recommendations from medical societies or Health Authorities, delays in obtaining results, and the lack of adequate reimbursement by the health insurance system. The goal of these surveys was to provide the French Health Authorities with an overview on nationwide DPD-deficiency screening practices and thus help to design recommendations for the standardization and improvement of the management and safety of cancer patients receiving FP-based chemotherapy.
Databáze: OpenAIRE
Externí odkaz: